The inquiry centers on whether Larimar and its leadership misled shareholders regarding the safety profile of nomlabofusp, a treatment for Friedreich's ataxia. On September 29, 2025, the company reported positive data from an open-label study but revealed that seven participants had suffered from anaphylaxis. Shares plummeted 33.66% that day, closing at $3.38.
Concerns intensified on June 29, 2026, when the firm confirmed the submission of a rolling Biologics License Application. Despite the regulatory milestone, the company disclosed that anaphylaxis had been reported in 10 of 43 patients. Following this update, the stock price dropped another 12.57% to close at $3.20 per share. Investors affected by these developments are encouraged to contact Danielle Peyton at Pomerantz LLP to discuss their legal options regarding potential breaches of fiduciary duty or corporate misconduct.
Comments (0)
No comments yet. Be the first!